Blackstone buys Takeda Japan Consumer Health Care for approximately JPY242 billion. TCHC's revenue for fiscal 2019 was JPY60 billion. Its OTC portfolio includes Alinamin, Japan's best-selling drug. The deal is expected to be closed by March 31, 2021.